Target Name: GATA6
NCBI ID: G2627
Other Name(s): GATA-binding factor 6 | GATA binding protein 6 | Transcription factor GATA-6 | GATA-6 | GATA6_HUMAN | GATA-binding protein 6

GATA6 as A Drug Target and Biomarker for Diseases

GATA6 (GATA-binding factor 6) is a non-coding RNA molecule that plays a critical role in gene regulation and has been linked to a number of diseases. In this article, we will explore GATA6 as a drug target and its potential as a biomarker for various diseases.

GATA6 is a key regulator of gene expression and has been shown to play a role in the regulation of stem cell proliferation and differentiation. GATA6 is a part of the GATA gene family, which includes a number of similar non-coding RNAs that share a conserved core region. The GATA gene family is known for its ability to regulate gene expression in a variety of organisms, including humans.

One of the unique features of GATA6 is its ability to interact with specific DNA sequences, known as GATCs (gene-activity trans-regulatory cis-elements). GATCs are short sequences of DNA that can interact with GATA6 and recruit its partners, such as the transcription factor p53, to a specific location on the DNA. This interaction between GATCs and GATA6 is critical for the regulation of gene expression and is a key feature of the GATA6 gene family.

GATA6 has been shown to be involved in a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, GATA6 has been shown to be involved in the regulation of stem cell proliferation and the development of cancer. In addition, GATA6 has also been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

As a drug target, GATA6 has the potential to be used to treat a wide range of diseases. For example, GATA6 has been shown to be involved in the regulation of stem cell proliferation and has been linked to the development of cancer. As a result, GATA6 may be a potential target for cancer therapies that target stem cell proliferation. In addition, GATA6 has also been shown to be involved in the regulation of gene expression and has been linked to the development of neurodegenerative diseases. As a result, GATA6 may be a potential target for therapies that target neurodegenerative diseases.

In addition to its potential as a drug target, GATA6 also has potential as a biomarker. The regulation of gene expression by GATA6 is a key feature of the GATA6 gene family, and its regulation is known to be associated with the development of various diseases. As a result, GATA6 may be a potential biomarker for a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

GATA6 has been shown to be involved in the regulation of gene expression in a variety of organisms, including humans. For example, GATA6 has been shown to play a role in the regulation of stem cell proliferation and has been linked to the development of cancer. In addition, GATA6 has also been shown to play a role in the regulation of gene expression in the regulation of cell division and has been linked to the development of neurodegenerative diseases.

In addition to its role in gene regulation, GATA6 has also been shown to play a role in the regulation of protein synthesis. GATA6 has been shown to interact with the protein translation factor eIF4F and has been shown to play a role in the regulation of protein synthesis. This interaction between GATA6 and eIF4F is important for the regulation of protein synthesis and may be a potential target for therapies that target protein synthesis.

GATA6 has also been shown to play a role in the regulation of cellular signaling pathways. GATA6 has been shown to interact with the protein

Protein Name: GATA Binding Protein 6

Functions: Transcriptional activator (PubMed:19666519, PubMed:27756709, PubMed:22750565, PubMed:22824924). Regulates SEMA3C and PLXNA2 (PubMed:19666519). Involved in gene regulation specifically in the gastric epithelium (PubMed:9315713). May regulate genes that protect epithelial cells from bacterial infection (PubMed:16968778). Involved in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression (By similarity). Binds to BMP response element (BMPRE) DNA sequences within cardiac activating regions (By similarity). In human skin, controls several physiological processes contributing to homeostasis of the upper pilosebaceous unit. Triggers ductal and sebaceous differentiation as well as limits cell proliferation and lipid production to prevent hyperseborrhoea. Mediates the effects of retinoic acid on sebocyte proliferation, differentiation and lipid production. Also contributes to immune regulation of sebocytes and antimicrobial responses by modulating the expression of anti-inflammatory genes such as IL10 and pro-inflammatory genes such as IL6, TLR2, TLR4, and IFNG. Activates TGFB1 signaling which controls the interfollicular epidermis fate (PubMed:33082341)

More Common Targets

GATA6-AS1 | GATAD1 | GATAD2A | GATAD2B | GATB | GATC | GATD1 | GATD1-DT | GATD3 | GATM | GATOR1 Complex | GAU1 | GBA1 | GBA2 | GBA3 | GBAP1 | GBE1 | GBF1 | GBGT1 | GBP1 | GBP1P1 | GBP2 | GBP3 | GBP4 | GBP5 | GBP6 | GBP7 | GBX1 | GBX2 | GC | GCA | GCAT | GCC1 | GCC2 | GCC2-AS1 | GCDH | GCFC2 | GCG | GCGR | GCH1 | GCHFR | GCK | GCKR | GCLC | GCLM | GCM1 | GCM2 | GCN1 | GCNA | GCNT1 | GCNT1P3 | GCNT2 | GCNT3 | GCNT4 | GCNT7 | GCOM1 | GCSAM | GCSAML | GCSAML-AS1 | GCSH | GCSHP3 | GCSIR | GDA | GDAP1 | GDAP1L1 | GDAP2 | GDE1 | GDF1 | GDF10 | GDF11 | GDF15 | GDF2 | GDF3 | GDF5 | GDF6 | GDF7 | GDF9 | GDI1 | GDI2 | GDI2P1 | GDNF | GDNF Family Receptor alpha | GDNF-AS1 | GDPD1 | GDPD2 | GDPD3 | GDPD4 | GDPD5 | GDPGP1 | GEM | GEMIN2 | GEMIN4 | GEMIN5 | GEMIN6 | GEMIN7 | GEMIN8 | GEMIN8P1 | GEMIN8P4 | GEN1 | general transcription factor IIF (TFIIF)